NKTR-102: Clinical Trials

7 trials of NKTR-102, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed. 4 Phase 2, 2 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 24Completed 4
Phase 32Completed 2
Phase 11Completed 1

Follow NKTR-102: new trials by email Literature Review of NKTR-102 trials Research Report on NKTR-102

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
NKTR-102, Eribulin, Ixabepilone - Metastasis, Breast Cancer
Phase 3CompletedNektar Therapeutics1782016-11-012023-04-14
Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer
Pegylated Irinotecan - Stage IV Non-small Cell Lung Cancer (NSCLC), Recurrent Non-small Cell Lung Cancer (NSCLC)
Phase 2CompletedJoel Neal272015-08-012023-12-12
A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety
NKTR-102 - Advanced Cancer, Metastatic Solid Tumors
Phase 1CompletedNektar Therapeutics332014-02-012016-12-22
Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma
Etirinotecan pegol - Anaplastic Astrocytomas, Anaplastic Oligodendrogliomas
Phase 2CompletedLawrence Recht202012-07-012016-02-24
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
NKTR-102, Treatment of Physician's Choice (TPC) - Locally Recurrent Breast Cancer, Metastatic Breast Cancer
Phase 3CompletedNektar Therapeutics8522011-12-012021-06-01
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
NKTR-102, irinotecan - Colorectal Cancer
Phase 2CompletedNektar Therapeutics832008-12-012021-07-12
Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer
NKTR-102 - Tumor, Breast Cancer
Phase 2CompletedNektar Therapeutics702008-10-012018-07-09

Conditions studied

Breast Neoplasms (4)  ·  Astrocytoma (1)  ·  Brain Neoplasms (1)  ·  Carcinoma (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Colorectal Neoplasms (1)  ·  Glioblastoma (1)  ·  Neoplasm Metastasis (1)  ·  Neoplasms (1)  ·  Oligodendroglioma (1)  ·  Small Cell Lung Carcinoma (1)

Sponsors

Nektar Therapeutics (5)  ·  Joel Neal (1)  ·  Lawrence Recht (1)

Countries

United States (7)  ·  Belgium (4)  ·  United Kingdom (4)  ·  Spain (3)  ·  Canada (2)  ·  France (2)  ·  Germany (2)  ·  Italy (2)  ·  Australia (1)  ·  India (1)  ·  Israel (1)  ·  Netherlands (1)  ·  Portugal (1)  ·  Russia (1)  ·  South Korea (1)

Top investigators

Alison Hannah, MD (2)  ·  Ivan Gergel, MD (1)  ·  Joel Neal (1)  ·  Lawrence Recht, MD (1)

Results publications

PMID 24095299, PMID 26482278, PMID 28360015, PMID 28612225, PMID 30957581, PMID 31074641, PMID 35552364, PMID 40877204